このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Panbela Therapeutics 将来の成長

Future 基準チェック /06

Panbela Therapeuticsの収益は年間4.3%で減少すると予測されていますが、年間収益は年間82.4%で増加すると予想されています。EPS は年間53%で増加すると予想されています。

主要情報

-4.3%

収益成長率

53.0%

EPS成長率

Biotechs 収益成長	30.3%
収益成長率	82.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	11 Apr 2023

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:X70 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	N/A	-52	N/A	N/A	2
12/31/2024	N/A	-32	N/A	N/A	2
12/31/2023	N/A	-22	N/A	N/A	2
12/31/2022	N/A	-35	-16	-15	N/A
9/30/2022	N/A	-34	-13	-12	N/A
6/30/2022	N/A	-31	-12	-12	N/A
3/31/2022	N/A	-12	-9	-9	N/A
12/31/2021	N/A	-10	-7	-7	N/A
9/30/2021	N/A	-7	-6	-6	N/A
6/30/2021	N/A	-7	-6	-6	N/A
3/31/2021	N/A	-5	-5	-5	N/A
12/31/2020	N/A	-5	-4	-4	N/A
9/30/2020	N/A	-5	-4	-4	N/A
6/30/2020	N/A	-5	-3	-3	N/A
3/31/2020	N/A	-6	-3	-3	N/A
12/31/2019	N/A	-6	-3	-3	N/A
9/30/2019	N/A	-6	-2	-2	N/A
6/30/2019	N/A	-6	-2	-2	N/A
3/31/2019	N/A	-6	-3	-3	N/A
12/31/2018	N/A	-6	-2	-2	N/A
9/30/2018	N/A	-7	-3	-3	N/A
6/30/2018	N/A	-8	-3	-3	N/A
3/31/2018	N/A	-7	-3	-3	N/A
12/31/2017	N/A	-10	-3	-3	N/A
9/30/2017	N/A	-10	-3	-3	N/A
6/30/2017	N/A	-10	-4	-4	N/A
3/31/2017	N/A	-10	-3	-3	N/A
12/31/2016	N/A	-5	-2	-2	N/A
9/30/2016	N/A	-4	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: X70今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: X70今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: X70今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: X70来年は収益がないと予測されています。

高い収益成長: X70来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: X70の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Panbela Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

Panbela Therapeutics, Inc. Announces Nasdaq Files A Form 25 Notification of Removal from Listing

Panbela Therapeutics, Inc. Announces Interim Data Analysis for its Ongoing ASPIRE Trial Pushed to First Quarter of 2025

Panbela Announces Poster Presentation At American Association for Cancer Research

Panbela Therapeutics, Inc. has filed a Follow-on Equity Offering.

The Nasdaq Stock Market Notifies Panbela Therapeutics That the Nasdaq Hearings Panel Has Determined to Delist the Company’s Common Stock

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Therapeutics, Inc. Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

Panbela Therapeutics Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(4)

Panbela Therapeutics, Inc. Announces Publication of Clinical Data Titled: Phase 1 Study of High-Dose DFMO, Celecoxib, Cyclophosphamide and Topotecan for Patients with Relapsed Neuroblastoma

Panbela Therapeutics, Inc. Announces second Independent Safety Review of the ASPIRE Registration Clinical Trial

Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves B Cell Function in Type 1 Diabetes

Panbela Therapeutics, Inc. Announces Acceptance of Polyamine Inhibitor Car-T Combination Abstract for Online Publication

Panbela Therapeutics, Inc. Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer

Panbela Announces Preliminary Safety Analysis for ASPIRE Trial

Panbela Therapeutics, Inc. Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.510816 million.

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023 to Regain Compliance with the Continued Listing Requirements of the Nasdaq Capital Market

Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023 to Regain Compliance with the Continued Listing Requirements of the Nasdaq Capital Market

Panbela Therapeutics Regains Compliance with Nasdaq Listing Standards

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.01875 million.

Panbela Therapeutics, Inc. Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF

Panbela Therapeutics, Inc. Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Panbela Therapeutics Receives a Notification Letter from Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Therapeutics, Inc. Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Therapeutics Receives a Letter from The Nasdaq Stock Market LLC Regarding Minimum Stockholders' Equity Requirement

Panbela Therapeutics, Inc. Receives Approval from Australian Human Research Ethics Committee to Expand Global Clinical Trial to Australia

Panbela Therapeutics, Inc. Announces the Publication of Preclinical Data from Studies of SBP-101

Less than half of directors are independent

Panbela Therapeutics, Inc. (NasdaqCM:PBLA) completed the acquisition of Cancer Prevention Pharmaceuticals, Inc.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘